20cm速递｜科创创新药ETF国泰（589720）涨超1.1%，政策优化与国际化进程助推行业结构性机会

Group 1 - The core viewpoint is that the pharmaceutical and chemical drug industry is showing multiple positive signals, with a recovery in the global pharmaceutical investment environment and strong demand in the CDMO sector [1] - The domestic CXO companies are leveraging their competitive advantages to boost downstream demand, while overseas CRO demand is recovering [1] - The industry is expected to return to positive growth by Q1 2025, with significant year-on-year increases in revenue and net profit [1] Group 2 - The Cathay Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which focuses on companies engaged in innovative drug research and development [2] - The index reflects the overall performance of listed companies in the innovative drug sector, emphasizing high growth and innovation in the biopharmaceutical industry [2] - The index can experience daily fluctuations of up to 20%, indicating its volatility and potential for significant short-term movements [2]